source
- Sarepta's FDA decision date; Flare gets Anna Protopapas as CEOPlus news about Deerfield, InflaRx, Praxis, Nuvectis, Pyxis Oncology, Vistagen, Arcutis Biotherapeutics and Nxera. 🔎 FDA to decide on future of Sarepta exon-skipping drugs by end of February: The…Endpoints · 28d ago↗ source
- Beeline ups its Series A round for immune drug workThe company, which was built by Bain Capital, has now raised more than $426 million in its quest to advance a portfolio of Bristol Myers drugs.BioPharma Dive · 28d ago↗ source
- Top FDA gene and cell therapy regulator to step downFollowing Vijay Kumar’s exit, acting CBER Director Karim Mikhail will also oversee a review office that has become a battleground for debates on FDA flexibility.BioPharma Dive · 28d ago